<DOC>
	<DOCNO>NCT02252159</DOCNO>
	<brief_summary>This Phase IV , multicenter , non-interventional , non-randomized , prospective , observational study adult population ( patient &gt; 18 year old ) men woman diagnose clinically overt PV follow either community academic medical center United States enrol 12-month period observe 36 month date last patient enrol .</brief_summary>
	<brief_title>Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices ( REVEAL )</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Nucleic Acid Synthesis Inhibitors</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Age â‰¥18 year Diagnosis Polycythemia Vera ( PV ) Willing able provide write informed consent Willing able complete patient assessment questionnaires either alone minimal assistance caregiver and/or train site personnel Under supervision physician current care PV include limited watchful waiting , acetylsalicylic acid ( ASA ) 81mg great , antithrombotic therapy , Phlebotomy ( PHL ) , Hydroxyurea ( HU ) , interferon ( recombinant pegylated ) , busulfan , anagrelide Participation active clinical trial study treatment blind Life expectancy &lt; 6 month Diagnosis myelofibrosis ( MF ) [ include primary MF , postPV MF , postessential thrombocythemia MF ( postET MF ) ] Diagnosis secondary Acute Myeloid Leukemia ( AML ) Diagnosis Myelodysplastic Syndrome ( MDS ) History active plan proceed allogeneic hematopoietic stem cell transplant next 3 month Splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antisickling Agents</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Nucleic Acid Synthesis Inhibitors</keyword>
</DOC>